首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

【24h】

Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs)

机译：珍珠研究结果（Geicam / 2013-02_cecog / BC.1.3.006）：帕尔巴昔米尔（PAL）与内分泌治疗（ET）与己酮受体（HR） - 阳性/人类组合的第3阶段试验表皮生长因子受体（她）2阴性转移性乳腺癌（MBC）患者（PTS），其疾病在芳香酶抑制剂上进行（AIS）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共4页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：珍珠研究结果（Geicam / 2013-02_cecog / BC.1.3.006）：帕尔巴昔米尔（PAL）与内分泌治疗（ET）与己酮受体（HR） - 阳性/人类组合的第3阶段试验表皮生长因子受体（她）2阴性转移性乳腺癌（MBC）患者（PTS），其疾病在芳香酶抑制剂上进行（AIS）
2. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102 [J] . Kornblum Noah, Zhao Fengmin, Manola Judith, Journal of Clinical Oncology . 2018,第16期

机译：随机二期试验氟斯特语加血管血清或安慰剂在绝经后妇女患有激素受体阳性，人表皮生长因子受体2阴性转移性乳腺癌抗性芳香酶抑制剂治疗：pre0102的结果
3. EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) = 50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES [J] . Cristofanilli Massimo, Harbeck Nadia, Rugo Hope, The Breast : . 2018,第Suppla1期

机译：疗效加上患者（PTS）中Palbociclib（P）的疗效加上患者（PTS）＆ = 50°Y，激素受体阳性（HR加）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）：亚组分析 2阶段3研究
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：PALOMA-3：在有激素受体阳性人类表皮生长因子受体2阴性的绝经前和绝经后妇女中使用或不使用帕博西利的氟维西汀的III期试验已在先前的内分泌治疗中进展阴性转移性乳腺癌—亚洲患者的安全性和有效性
7. PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients [O] . Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, 2017

机译：paLOma-3：氟维司群有或没有palbociclib的绝经前和绝经后妇女的III期试验激素受体阳性，人类表皮生长因子受体2 - 先前内分泌治疗进展的阴性转移性乳腺癌 - 亚洲患者的安全性和有效性

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号